Arteris COO sells 1,993 shares in planned trades

Arteris, Inc. Chief Operating Officer Laurent R. Moll reported small open-market sales of company stock under a pre-set trading plan.

Rhea-AI Filing Summary

Arteris, Inc. Chief Operating Officer Laurent R. Moll reported small open-market sales of company stock under a pre-set trading plan. He sold a total of 1,993 shares of common stock at a weighted average price around $19.90 per share and continues to hold 278,979 shares directly.

Insider Trade Summary 10b5-1

Net Seller: 1,993 shares

Net Sell 2 txns

Insider Moll Laurent R

Role Chief Operating Officer

Sold 1,993 shs ($40K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,003	$19.90	$20K
Sale	Common Stock	990	$19.90	$20K

Holdings After Transaction: Common Stock — 278,979 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on March 12, 2025.
2. F2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.90 to $19.91 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 1,993 shares First sale: 1,003 shares at $19.90 Second sale: 990 shares at $19.90 +3 more

6 metrics

Shares sold 1,993 shares Total common stock sold across two open-market transactions

First sale 1,003 shares at $19.90 Open-market sale on April 13, 2026

Second sale 990 shares at $19.90 Open-market sale on April 10, 2026

Weighted price range $19.90–$19.91 Range of prices for multiple trades within the reported sales

Shares held after 278,979 shares Direct Arteris common stock ownership after the transactions

Net insider direction net-sell of 1,993 shares Aggregate effect of reported Form 4 transactions

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open-market sale

3 terms

Rule 10b5-1 trading plan regulatory

"Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on March 12, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported in Column 4 is a weighted average sale price."

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Arteris (AIP) report for Laurent R. Moll?

Arteris reported that Chief Operating Officer Laurent R. Moll sold 1,993 shares of common stock in two open-market transactions. These trades occurred at prices around $19.90 per share and were executed under a pre-arranged Rule 10b5-1 trading plan.

At what prices did the Arteris (AIP) COO sell his shares?

The reported weighted average sale price was $19.90 per share. Footnotes explain that individual trades took place in a narrow range between $19.90 and $19.91 per share, reflecting multiple small executions during the sale process.

How many Arteris (AIP) shares does Laurent R. Moll hold after the Form 4 sales?

Following the reported transactions, Chief Operating Officer Laurent R. Moll directly owns 278,979 shares of Arteris common stock. This figure appears in the post-transaction holding column and shows he retains a substantial equity position after the small open-market sales.

Were the Arteris (AIP) insider sales made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2025. Such plans pre-schedule trades, helping separate routine portfolio management from discretionary market-timing decisions by insiders.

How many separate transactions are included in this Arteris (AIP) Form 4?

The Form 4 shows two non-derivative transactions in common stock, both coded as open-market sales. One involved 1,003 shares on April 13, 2026, and the other 990 shares on April 10, 2026, totaling 1,993 shares sold during the disclosed period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/14/2026 - 04:07 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moll Laurent R

(Last) (First) (Middle)

C/O ARTERIS, INC.

900 E. HAMILTON AVE., SUITE 300

(Street)

CAMPBELL CALIFORNIA 95008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/10/2026		S(1)		990	D	$19.9	279,982	D
Common Stock	04/13/2026		S(1)		1,003	D	$19.9(2)	278,979	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on March 12, 2025.

2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.90 to $19.91 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Paul Alpern, as Attorney-in-Fact for Moll Laurent R	04/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)